Category Archives: New Hampshire Stem Cells

Vapotherm (NYSE:VAPO) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Vapotherm and Invivo Therapeutics net margins, return on equity and return on assets.

Institutional & Insider Ownership

60.0% of Vapotherm shares are owned by institutional investors. Comparatively, 7.0% of Invivo Therapeutics shares are owned by institutional investors. 34.4% of Vapotherm shares are owned by insiders. Comparatively, 0.3% of Invivo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Vapotherm and Invivo Therapeutics, as provided by MarketBeat.

Vapotherm presently has a consensus price target of $26.50, indicating a potential upside of 143.57%. Given Vapotherms higher probable upside, research analysts plainly believe Vapotherm is more favorable than Invivo Therapeutics.

Earnings & Valuation

This table compares Vapotherm and Invivo Therapeutics top-line revenue, earnings per share and valuation.

Invivo Therapeutics has lower revenue, but higher earnings than Vapotherm. Vapotherm is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Vapotherm beats Invivo Therapeutics on 6 of the 11 factors compared between the two stocks.

About Vapotherm

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.

More:
Head-To-Head Analysis: Vapotherm (NYSE:VAPO) & Invivo Therapeutics (NYSE:NVIV) - TechNewsObserver

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 80 percent of presentations prepared by external authors

ST. HELIER, Jersey--(BUSINESS WIRE)--#btsm--Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO) on Nov. 20 through Nov. 24 in Phoenix. Presentations on Tumor Treating Fields cover a broad and growing range of topics. External authors prepared 34 of the 43 presentations.

The oral presentations on Tumor Treating Fields include an EF-14 post hoc subgroup analysis on tumor growth rates, and the pilot study results of Tumor Treating Fields combined with radiotherapy and temozolomide for the treatment of newly diagnosed glioblastoma.

Highlights among poster presentations include the combinations of Tumor Treating Fields with other therapies such as radiation and immunotherapies, simulations, health economics and outcomes research, patient advocacy, and research on the mechanism of action.

Year after year, it is amazing to see the continued focus on Tumor Treating Fields at the SNO Annual Meeting, said Novocure CEO Asaf Danziger. From our first presentation at SNO in 2008 to today, more than 250 abstracts on Tumor Treating Fields have been included at one of the most important conferences in neuro-oncology worldwide. I am proud of our team for their relentless focus on innovative research and for their consistent drive in raising awareness of our therapy among the scientific community. We look forward to another productive year at SNO.

(Abstract #: ACTR-46) Tumor Treating Fields combined with radiotherapy and temozolomide for the treatment of newly diagnosed glioblastoma: Final results from a pilot study. R. Grossman. 2:45 to 2:50 p.m. MST Nov. 22.

(Abstract #: RTHP-28) TTFields treatment affects tumor growth rates: A post-hoc analysis of the pivotal phase 3 EF-14 trial. Z. Bomzon. 4:05 to 4:10 p.m. MST Nov. 22.

(Abstract #: QOLP-24) Patients/parents experiences of receiving Optune delivered tumor treatment fields: A Pediatric Brain Tumor Consortium Study: PBTC-048. J. Lai. 7:50 to 7:54 p.m. MST Nov. 22.

(Abstract #: RDNA-10) TTFields treatment planning for targeting multiple lesions spread throughout the brain. Z. Bomzon. 7:30 to 9:30 p.m. MST Nov. 22. (Radiation Biology and DNA Repair/Basic Science)

(Abstract #: NIMG-20) Evaluation of head segmentation quality for treatment planning of tumor treating fields in brain tumors. Z. Bomzon. 7:30 to 9:30 p.m. MST Nov. 22. (Neuro-Imaging/Clinical Research)

(Abstract #: HOUT-24) Challenges and successes in the global reimbursement of a breakthrough medical technology for treatment of glioblastoma multiforme. C. Proescholdt. 7:30 to 9:30 p.m. MST Nov. 22. (Health Outcome Measures/Clinical Research)

(Abstract #: EXTH-02) The blood brain barrier (BBB) permeability is altered by Tumor Treating Fields (TTFields) in vivo. E. Schulz. 7:30 to 9:30 p.m. MST Nov. 22. (Experimental Therapeutics/Basic Science)

(Abstract #: IMMU-06) TTFields induces immunogenic cell death and STING pathway activation through cytoplasmic double-stranded DNA in glioblastoma cells. D. Chen. 7:30 to 9:30 p.m. MST Nov. 22. (Immunology/Basic Science)

(Abstract #: DRES-06) Prostaglandin E Receptor 3 mediates resistance to Tumor Treating Fields in glioblastoma cells. D. Chen. 7:30 to 9:30 p.m. MST Nov. 22. (Drug Resistance/Basic Science)

(Abstract #: EXTH-34) In vitro tumor treating fields (TTFields) applied prior to radiation enhances the response to radiation in patient-derived glioblastoma cell lines. S. Mittal. 7:30 to 9:30 p.m. MST Nov. 22. (Experimental Therapeutics/Basic Science)

(Abstract #: CSIG-20) Effect of tumor-treating felds (TTFields) on EGFR phosphorylation in GBM cell lines. M. Reinert. 7:30 to 9:30 p.m. MST Nov. 22. (Cell Signaling and Signaling Pathways/Basic Science)

(Abstract #: CBMT-14) The dielectric properties of brain tumor tissue. M. Proescholdt. 7:30 to 9:30 p.m. MST Nov. 22. (Cell Biology and Metabolism/Basic Science)

(Abstract #: CSIG-26) Is intrinsic apoptosis the signaling pathway activated by tumor-treating fields for glioblastoma. K. Carlson. 7:30 to 9:30 p.m. MST Nov. 22. (Cell Signaling and Signaling Pathways/Basic Science)

(Abstract #: ATIM-08) Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-nave, recurrent glioblastoma. Y. Odia. 7:30 to 9:30 p.m. MST Nov. 22. (Adult Clinical Trials Immunologic/Clinical Research)

(Abstract #: ACTR-60) A phase 2, historically controlled study testing the efficacy of TTFields with adjuvant temozolomide in high-risk WHO grade II and III astrocytomas (FORWARD). A. Allen. 7:30 to 9:30 p.m. MST Nov. 22. (Adult Clinical Trials - Non-Immunologic/Clinical Research)

(Abstract #: TMIC-54) Comparison of cellular features at autopsy in glioblastoma patients with standard treatment of care and tumor treatment fields. A. Lowman. 7:30 to 9:30 p.m. MST Nov. 22. (Tumor Microenvironment/Basic Science)

(Abstract #: ACTR-26) Safety and efficacy of bevacizumab plus Tumor Treating Fields (TTFields) in patients with recurrent glioblastoma (GBM): data from a phase II clinical trial. J. Fallah. 7:30 to 9:30 p.m. MST Nov. 22. (Adult Clinical Trials Non-immunologic/Clinical Research)

(Abstract #: RBTT-02) Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial. V. Gondi. 7:30 to 9:30 p.m. MST Nov. 22. (Randomized Brain Tumor Trials in Development/Clinical Research)

(Abstract #: INNV-16) Complete response of thalamic IDH wildtype glioblastoma after proton therapy followed by chemotherapy together with Tumor Treating Fields. M. Stein. 7:30 to 9:30 p.m. MST Nov. 22. (Innovations in Patient Care/Clinical Research)

(Abstract #: INNV-20) A systematic review of tumor treating fields therapy for primary for recurrent and glioblastoma. P. Shah. 7:30 to 9:30 p.m. MST Nov. 22. (Innovations in Patient Care/Clinical Research)

(Abstract #: STEM-16) Dual Inhibition of Protein Arginine Methyltransferase 5 and Protein Phosphatase 2a Enhances the Anti-tumor Efficacy in Primary Glioblastoma Neurospheres. H. Sur. 7:30 to 9:30 p.m. MST Nov. 22. (Stem Cells/Basic Science)

(Abstract #: CBMT-13) 3DEP system to test the electrical properties of different cell lines as predictive markers of optimal tumor treating fields (TTFields) frequency and sensitivity. M. Giladi. 5 to 7 p.m. MST Nov. 23. (Cell Biology and Metabolism/Basic Science)

(Abstract #: EXTH-37) A novel transducer array layout for delivering Tumor Treating Fields to the spine. Z. Bomzon. 5 to 7 p.m. MST Nov. 23. (Experimental Therapeutics/Basic Science)

(Abstract #: NIMG-41) Rapid and accurate creation of patient-specific computational models for GBM patients receiving Optune therapy with conventional imaging (T1w/PD). Z. Bomzon. 5 to 7 p.m. MST Nov. 23. (Neuro-Imaging/Clinical Research)

(Abstract #: HOUT-17) Utilities of rare cancers like malignant pleural mesothelioma and glioblastoma multiforme - do they compare? C. Proescholdt. 5 to 7 p.m. MST Nov. 23. (Health Outcome Measures/Clinical Research)

(Abstract #: INNV-17) Innovative educational approaches to enhance patient and caregiver understanding of Optune for glioblastoma. M. Shackelford. 5 to 7 p.m. MST Nov. 23. (Innovations in Patient Care/Clinical Research)

(Abstract #: EXTH-05) Therapeutic implications of TTFields induced DNA damage and replication stress in novel combinations for cancer treatment. N. Karanam. 5 to 7 p.m. MST Nov. 23. (Experimental Therapeutics/Basic Science)

(Abstract #: EXTH-31) Combination of tumor treating fields (TTFields) and paclitaxel produces additive reductions in proliferation and clonogenicity in patient-derived metastatic non-small cell lung cancer (NSCLC) cells. S. Michelhaugh. 5 to 7 p.m. MST Nov. 23 (Experimental Therapeutics/Basic Science)

(Abstract #: EXTH-53) Tumor Treating Fields leads to changes in membrane permeability and increased penetration by anti-glioma drugs. E. Chang. 5 to 7 p.m. MST Nov. 23. (Experimental Therapeutics/Basic Science)

(Abstract #: RDNA-01) Tubulin and microtubules as molecular targets for TTField therapy. J. Tuszynski. 5 to 7 p.m. MST Nov. 23. (Radiation Biology and DNA Repair/Basic Science)

(Abstract #: SURG-01) OptimalTTF-1: Final results of a phase 1 study: First glioblastoma recurrence examining targeted skull remodeling surgery to enhance Tumor Treating Fields strength. A. Korshoej. 5 to 7 p.m. MST Nov. 23. (Surgical Therapy/Clinical Research)

(Abstract #: ATIM-39) Phase 2 open-labeled study of adjuvant temozolomide plus Tumor Treating Fields plus Pembrolizumab in patients with newly diagnosed glioblastoma (2-THE-TOP). D. Tran. 5 to 7 p.m. MST Nov. 23. (Adult Clinical Trials Immunologic/Clinical Research)

(Abstract #: ACTR-49) Initial experience with scalp preservation and radiation plus concurrent alternating electric tumor-treating fields (SPARE) for glioblastoma patients. A. Song. 5 to 7 p.m. MST Nov. 23. (Adult Clinical Trials - Non-Immunologic/Clinical Research)

(Abstract #: RTHP-25) TTFields dose distribution alters tumor growth patterns: An imaging-based analysis of the randomized phase 3 EF-14 trial. M. Ballo. 5 to 7 p.m. MST Nov. 23. (Radiation Therapy/Clinical Research)

(Abstract #: ACTR-19) Report on the combination of Axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma. E. Schulz. 5 to 7 p.m. MST Nov. 23. (Adult Clinical Trials - Non-Immunologic/Clinical Research)

(Abstract #: PATH-47) TTF may apply selective pressure to glioblastoma clones with aneuploidy: a case report. M. Ruff. 5 to 7 p.m. MST Nov. 23. (Molecular Pathology and Classification Adult and Pediatric/Clinical Research)

(Abstract #: RARE-39) Combination of Tumor Treating Fields (TTFields) with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis. L. Lazaridis. 5 to 7 p.m. MST Nov. 23. (Rare Tumors/Clinical Research)

(Abstract #: ACTR-31) The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER: TTFields in Germany in routine clinical care). O. Bahr. 5 to 7 p.m. MST Nov. 23. (Adult Clinical Trials Non-Immunologic/Clinical Research)

(Abstract #: INNV-09) Clinical efficacy of tumor treating fields for newly diagnosed glioblastoma. Y. Liu. 5 to 7 p.m. MST Nov. 23. (Innovations in Patient Care/Clinical Research)

(Abstract #: EXTH-61) Celecoxib Improves Outcome of Patients Treated with Tumor Treating Fields. K. Swanson. 5 to 7 p.m. MST Nov. 23. (Experimental Therapeutics/Basic Science)

(Abstract #: INNV-23) Glioblastoma and Facebook: An Analysis Of Perceived Etiologies and Treatments. N. Reddy. 5 to 7 p.m. MST Nov. 23. (Innovations in Patient Care/Clinical Research)

(Abstract #: INNV-12) Outcomes in a Real-world Practice For Patients With Primary Glioblastoma: Impact of a Specialized Neuro-oncology Cancer Care Program. N. Banerji. 5 to 7 p.m. MST Nov. 23. (Innovations in Patient Care/Clinical Research)

(Abstract #: RBTT-11): NRG Oncology NRG-BN006: A Phase II/III Randomized, Open-label Study of Toca 511 and Toca FC With Standard of Care Compared to Standard of Care in Patients With Newly Diagnosed Glioblastoma. M. Ahluwalia. 5 to 7 p.m. MST Nov. 23. (Randomized Brain Tumor Trials Development/Clinical Research)

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocures commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit http://www.novocure.com or follow us at http://www.twitter.com/novocure.

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

The NovoTTF-100L System is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.

Important Safety Information

Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Do not use the NovoTTF-100L System in patients with MPM with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc.

Use of Optune for GBM or the NovoTTF-100L System for MPM together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune for GBM or the NovoTTF-100L System for MPM in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune and the NovoTTF-100L System may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Optune and the NovoTTF-100L System can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure.

The most common (10%) adverse events involving Optune in combination with chemotherapy in patients with GBM were thrombocytopenia, nausea, constipation, vomiting, fatigue, convulsions, and depression.

The most common (10%) adverse events related to Optune treatment alone in patients with GBM were medical device site reaction and headache. Other less common adverse reactions were malaise, muscle twitching, and falls related to carrying the device.

The most common (10%) adverse events involving the NovoTTF-100L System in combination with chemotherapy in patients with MPM were anemia, constipation, nausea, asthenia, chest pain, fatigue, device skin reaction, pruritus, and cough.

Other potential adverse effects associated with the use of the NovoTTF-100L System include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical site reaction and skin breakdown/skin ulcer.

If the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune and the NovoTTF-100L System treatment.

Do not prescribe Optune or the NovoTTF-100L System for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune and the NovoTTF-100L System in these populations have not been established.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocures current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as anticipate, estimate, expect, project, intend, plan, believe or other words and terms of similar meaning. Novocures performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Quarterly Report on Form 10-Q filed on July 25, 2019, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Media and Investor Contact:

More video from this section

Visit link:
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Arizona Daily Star

The thought of spaceflight may make the heart skip a beat, but actually travelling beyond Earth could alter the organs cells.

With extended stays aboard the International Space Station (ISS) commonplace, and the likelihood of humans spending longer periods in space increasing, there is a need to better understand the effects of micro-gravity on cardiac function.

New research suggests heart muscle cells derived from stem cells have a remarkable ability to adapt to their environment during and after spaceflight.

Scientists examined cell-level cardiac function and gene expression in human heart cells cultured aboard the International Space Station for five-and-a-half weeks.

They found that exposure to micro-gravity changed the expression of thousands of genes, but largely normal patterns reappeared within 10 days after returning to Earth.

Senior study author, Joseph Wu, of Stanford University School of Medicine, said: Our study is novel because it is the first to use human induced pluripotent stem cells to study the effects of spaceflight on human heart function.

Micro-gravity is an environment that is not very well understood, in terms of its overall effect on the human body, and studies like this could help shed light on how the cells of the body behave in space, especially as the world embarks on more and longer space missions such as going to the moon and Mars.

Until now, most studies on how the heart reacts to micro-gravity have been conducted in either non-human models or at tissue, organ or systemic level.

To address this, the beating cells were launched to the ISS aboard a SpaceX spacecraft as part of a commercial resupply service mission.

Simultaneously, they were also cultured on Earth for comparison purposes.

When they returned to the planet, the cells showed normal structure and morphology.

However, they did adapt by modifying their beating pattern and calcium recycling patterns.

Researchers sequenced the cells harvested at four-and-a-half weeks aboard the ISS, and 10 days after returning to Earth.

Results showed that 2,635 genes were differentially expressed among flight, post-flight, and ground control samples.

Most notably, gene pathways related to mitochondrial function were expressed more in the space-flown cells, according to the research published in the Stem Cells Reports journal.

A comparison of the samples revealed the space cells adopted a unique gene expression pattern during spaceflight, which reverted to one that is similar to ground-side controls upon return to normal gravity.

Dr Wu added: Were surprised about how quickly human heart muscle cells are able to adapt to the environment in which they are placed, including micro-gravity.

These studies may provide insight into cellular mechanisms that could benefit astronaut health during long-duration spaceflight, or potentially lay the foundation for new insights into improving heart health on Earth.

Original post:
Spaceflight alters human heart cells, but they mostly return to normal: Study - Hampshire Chronicle

Qrons, a New York-based biotechnology start-up, has announced an Intellectual Property (IP) License Agreement with Dartmouth College, New Hampshire, to develop 3D printable implants to treat penetrating or traumatic brain injuries (TBI).

TBI is caused by sudden damage to the brain from an external force. As stated by the World Health Organization (WHO), TBI has resulted in a large number of deaths and impairments leading to permanent disabilities. Such injuries require long-term care and incur approximately $76 billion in medical costs annually.

As a result of this agreement, Qrons has received an exclusive worldwide license of IP associated with 3D printable materials in the fields of human and animal health. Ido Merfeld, Co-founder and Head of Product, Qrons, stated:

The intellectual property covered by this license has been instrumental in helping us advance our research on the treatment of penetrating brain injuries. We believe combining Qrons proprietary hydrogel with customizable 3D printing capabilities is an innovative approach to treating traumatic brain injuries, for which there are limited treatments.

Traumatic brain injuries

According to Qrons, treating patients with TBI can be difficult as each injury is different in size, shape, spread, and location. While penetrating injuries cause mechanical damage to brain tissue, non-penetrating injuries inflict widespread neuronal disruption.

In an effort to repair TBIs, researchers from the company, which was founded in 2016, have identified thateach injured site must receive a continuous flow of neuro-protective and neuro-regenerative agents. This prevents further neuronal damage and stimulates neurons to migrate to the injury site, regrow axonal processes and regenerate brain tissue.

Thus, genetically modified mesenchymal stem cells (MSCs) are being developed to secrete these agents to continuously and safely drive TBI repair mechanisms. Qrons is using the patented process Mechanically interlocked molecules-based materials for 3D printing to create injury-specific3D printable implants for TBIs.

Jonah Meer, Co-founder and CEO, added, There is a great need for our promising treatments, and this technology is an integral part of our work to develop innovative 3D printable, biocompatible advanced materials.

Cell-synthetic hydrogel-based 3D printing

Working with advanced stem cell-synthetic hydrogel-based solutions, the Qrons research team is collaborating with Chenfeng Ke, Associate Professor of Chemistry, Dartmouth College, a member of Qrons Scientific Advisory Board and Qianming Lin, Ph.D. candidate an inventor of the licensed 3D process.

The new agreement provides for the payment by Qrons of initial and annual license fees and royalty payments based upon Qrons product sales.Professor Ke, stated, We are excited to partner with Qrons and continue the development of smart hydrogels with 3D printing capability for the treatment of traumatic brain injuries.

For all the latest 3D printing news,subscribe to our free newsletter hereandfollow our active social media accounts.

Looking for a career in additive manufacturing? Visit3D Printing Jobsfor a selection of roles in the industry.

Featured image shows aCT brain scan of a cranium with TBI. Image via Qrons.

Continue reading here:
Qrons and Dartmouth researchers to develop 3D printable implants for Traumatic Brain Injuries - 3D Printing Industry

MANCHESTER Its never too early.

This includes reaching out to kids in kindergarten through second grade to create the earliest of worker pipelines.

Thats when theyre deciding what to be when they grow up, said Barbara Hopkins, whos working on one of several pilot projects that the Advanced Regenerative Manufacturing Institute/BioFabUSA is funding.

Hopkins, as part of the effort by the University of New Hampshires Joan and James Leitzel Center for Mathematics, Science, and Engineering Education, is producing unit lessons for teachers to use as soon as this fall to get kids interested in the life sciences and eventually pursuing a career.

The aim is to get kids from K-12 involved and become a model for other states.

ARMI/BioFabUSA, which inventor Dean Kamen spearheaded, has green-lighted several projects to get students interested in the life sciences and snare the workers of tomorrow.

Its all about looking at different learning channels, said Mike Decelle, chief workforce officer for ARMI and dean of UNH Manchester. If successful, can this then be a national initiative?

Many companies in New Hampshire and other states are reaching into high schools and middle schools to introduce their industries to students and attract some that will undertake internships and perhaps full-time employment.

Another project involves partnering with the Girl Scouts of the Green and White Mountains to develop a new biofabrication curriculum and a patch for girls age 5 to 17.

Were going to do some really good programs that we already know are tested and theyre going to be more interested in STEM as a result of them, Patricia Casey, the Girl Scouts director of advancement, told people attending the ARMI/BioFabUSA fall summit in the Millyard last week.

She said the dedicated Girl Scout patch probably wont be available until next year.

A study showed 74 percent of Girl Scouts surveyed were interested in STEM science, technology, engineering and mathematics but only 13 percent of them said a career in STEM was their first choice, Casey said.

In another project, the SEE Science Center in Manchester used a tool kit from ARMI that let kids take a fake heart, made from a gelatinous substance, and use an eye-dropper to pretend they were adding or subtracting cells from the fake heart, which turned red or white depending on what they were doing.

Kids feel like theyre doing some real science here, said Peter Gustafson, the centers operations director.

SEE also will develop a field trip experience.

The goal is to offer programs that can be a model for other museums, Decelle said.

ARMI/BioFabUSA is providing roughly between $100,000 and $200,000 for each project, according to Decelle.

Still doing product development, he said. Everything starts small and then we we think: Do we scale it?

Hopkins said lesson plans for teachers will feature videos of scientists and engineers talking about why they are in their industry and what led them there.

Stories warm peoples hearts, she said after her talk. People remember the stories.

Tapping kids wonderment is a chief goal.

How do you grow curiosity rather than shut it down, Hopkins said. If were not challenging our kids in the classroom, theyre going to challenge themselves outside of the school and thats where they get in trouble if were not challenging them in the classrooms.

Another project involves CAST, a nonprofit based in Wakefield, Mass., that will develop student interest in science.

CAST has partnered with two career & technical education schools in Nashua and at the Manchester School of Technology.

Our goal is really to make sure that more people can engage in the education training, work opportunities that allow them to be productive members of the workforce of today, the workforce of tomorrow, said Sam Johnston, director of postsecondary education and workforce development at CAST.

One effort is working on co-designing a mobile app allowing users to explore biofabrication, a process of producing living and non-living biological products from raw materials, such as living cells.

Decelle said he hopes the CAST work will serve as a pipeline to higher ed, a pipeline to industry.

This problem isnt New Hampshires alone.

In Arkansas, for example, the University of Arkansas Cooperative Extension Service with public- and private-sector partners teamed up to create a strategic planning and development program called Breakthrough Solutions. It produced a 2017 report, Creating an Education & Workforce Pipeline for Your Community/Region.

For education and workforce development to be effective, it requires various stakeholders to communicate with each other about the needs, opportunities and issues facing the workforce and employers in your community, the report said. This may require forming network hubs organizations, coalitions or alliances in which stakeholders meet on a regular basis to share information and discuss issues.

The report included a flow chart titled talent pipeline with data with grades kindergarten through sixth listed on one square.

A major employer recently stated that they are not just interested in the current workforce in a particular community; they want to know about the pipeline the education and workforce development system that will produce an effective workforce for years to come, the report read.

Whats Working, a series exploring solutions for New Hampshires workforce needs, is sponsored by the New Hampshire Solutions Journalism Lab at the Nackey S. Loeb School of Communications and is funded by Eversource, the New Hampshire Charitable Foundation, Dartmouth-Hitchcock Medical Center, the New Hampshire College & University Council, Northeast Delta Dental and the New Hampshire Coalition for Business and Education.

Contact reporter Michael Cousineau at mcousineau@unionleader.com. To read stories in the series, visit unionleader.com/whatsworking.

Visit link:
Finding tomorrow's workers in kindergarten? | What's Working - The Union Leader

Every year traumatic brain injuries (TBI) affect an average of 69 million individuals worldwide. Although the number is less than one percent of the total global population, it is large enough to draw attention from researchers and companies trying to ease the pain and suffering related to the injury, which is usually the result of a fall, a sports injury and especially traffic accidents. In the United States, it is one of the leading causes of death and disability among children and young adults. With so many biotechnology companies springing up to resolve, via bioprinting, many common afflictions and diseases, one of them has been developing advanced stem cell-based solutions since 2016 to combat neuronal injuries, with a particular focus on TBI and concussions.

Qrons, headquartered in New York, is now going further with their innovative research after they announced an agreement with Dartmouth College, in New Hampshire, for an exclusive worldwide license to develop innovative 3D printable biocompatible materials to treat penetrating brain injuries, and more.

The agreement, signed October on 2, allows Qrons to use a patented 3D process entitled Mechanically Interlocked Molecules-based Materials for 3D Printing as part of its injury-specific 3D printable implants to treat penetrating brain injuries. Qrons is also a funding party to a sponsored research agreement with Dartmouth to advance the license or ownership of additional intellectual property, and the companys research team is already working closely with Chenfeng Ke, the inventor of the licensed 3D process and an Assistant Professor at the universitys Department of Chemistry, to develop innovative 3D printable, biocompatible advanced materials.

Chenfeng Ke

Chenfeng Ke is currently leading the Ke Functional Materials Group Labat Dartmouth, which focuses on syntheses and applications of polymeric materials for storage/separation and 3D printing applications. According to the lab, the research scheme overlaps organic synthesis, crystal engineering, polymer synthesis, materials characterization, and 3D printing, with an emphasis on the design of polymeric materials that are noncovalently assembled.

We are excited to partner with Qrons and continue the development of smart hydrogels with 3D printing capability for the treatment of traumatic brain injuries, stated Ke, who is also a member of Qrons Scientific Advisory Board.

Today, current treatments to help patients regain function after a TBI focus on reducing secondary injuries, mainly rehabilitation in a hospital or specialized therapy center. It usually involves a physical therapist and occupational specialist to help patients relearn how to walk, talk, and carry out other everyday tasks. Qrons claims that this treatment can partially reduce further damage but do little or nothing to heal the brain.

At Qrons, researchers use a multi-disciplinary approach to treat this highly complex condition, by integrating a 3D printable, customized scaffold with innovative, engineered mesenchymal stem cells (MSCs) that target brain injuries to regenerate damaged tissue. The company suggests that these genetically modified MSCs offer a mechanism to secrete a continuous flow of neuro-protective and neuro-regenerative agents to drive TBI repair mechanisms. The agents can prevent further neuronal damage and have the potential to stimulate neurons to migrate to the injury site, regrow axonal processes and regenerate brain tissue.

Qrons already has two product candidates for treating TBIs, both integrating proprietary, modified MSCs and smart synthetic material. The QS100, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries, and QS200, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions.

The exclusive worldwide license for 3D printable materials in the fields of human and animal health will enhance the companys research, leading to further innovations in a niche field.

The intellectual property covered by this license has been instrumental in helping us advance our research on the treatment of penetrating brain injuries, commented Ido Merfeld, Qrons Co-founder and Head of Product. We believe combining Qrons proprietary hydrogel with customizable 3D printing capabilities is an innovative approach to treating traumatic brain injuries, for which there are limited treatments.

One of 111 bioprinting companies in the world, Qrons is moving fast to research novel techniques for promoting neural recovery. Throughout the last three years, they have entered into research agreements with Ariel University, based in Israel to develop and commercialize products for neuronal tissue regeneration and repair, completed the first in vivo animal experiments for the QS100 and are close to beginning pre-clinical experiments for the QS200.

Jonah Meer

Jonah Meer, also co-founder and CEO, said that there is a great need for our promising treatments, and this technology is an integral part of our work to develop innovative 3D printable, biocompatible advanced materials.

As the widespread impact of TBI continues to grow, solutions like the ones proposed by Qrons could mean a different lifestyle for survivors.

[Images: Qrons and Dartmouth College]

Originally posted here:
Qrons is Developing 3D Printable Implants to Treat Brain Injuries - 3DPrint.com

Arthritis & Joint Conditions

There is a time and place for medication and surgery, and finally there is a safe and effective place for self-healing biologics such as Stem Cell Exosome Therapy.

Please keep in mind this is not a medication or treatment specifically for arthritis or any other condition. This is a regenerative therapy cleared and regulated by the FDA. The products we use are FDA registered and processed in accordance with 21 CFR 1271 for Homologous Use to cover and protect tissues by providing cushioning, lubrication, and support.

The Center for Wellbeing utilizes Stem Cell Exosomes derived from perinatal tissue (amniotic, placental, umbilical cord and Whartons Jelly).

The exosomes from mesenchymal cells and are known to have three very important properties:

Because the exosomes are not live cells, they have the concentrated benefits of day 0 MSCs without having to use live stem cells. They are compatible with everyone and they will not be rejected by the immune system. Studies show they are far more potent than older stem cells, such as those found in the bone marrow or fat of the patient.

Stem Cell Exosomes Next Generation Biologic

Not all stem cell derived products are created equal.

The Medical Team here at the Center for Wellbeing provide personalized protocols using the most effective, safe and advanced regenerative therapies available. Exosomes are cell-derived nanoparticles that play a pivotal role in cell to cell communication and are involved in a wide range of physiological processes. They are small vesicles that look like tiny bubbles and are released by a variety of cell types, including mesenchymal stem cells from perinatal tissue (amniotic, placental, umbilical cord and Whartons Jelly). We have always been aware that the exosomes from mesenchymal stem cells are the power house messengers signaling a cascade of cellular functions activating healing and repair. This includes upregulating genes in order to facilitate or speed up the healing process.

The research and technology has advanced enough that we can now harness and isolate the exosomes (messengers) without the need of live stem cells. Exosomes are available in a concentrated form to provide a more effective patient outcome. Exosomes also allow for more applications because they cross the blood brain barrier and research shows they help systemic inflammatory conditions.

A bit more technical information about mesenchymal stem cell exosomes: They have an important role in the transfer of proteins, mRNA and miRNA and other bioactive molecules between cells and regulate gene expression in recipient cells, thus influencing various molecular pathways. After extensive research and collaborating with doctors around the country to gain knowledge and proof of results, we made the decision to bring this game changing therapy to our patients. Together with our Medical Director and New Hampshire Board Certified Nurse Practitioners, we use the most advanced and personalized protocols to address your condition. The key advantage for this type of Regenerative Medicine therapy is that it does not require any surgery and the results have proven to far exceed the common surgery-based autologous procedures. Your recovery is faster with far less potential for complications.

In scientific terms, mesenchymal stem cells are multipotent stromal (connective tissue) cells that stimulates your body to differentiate them into a variety of cell types, including neurons, cartilage, fat, blood (red, white or platelet blood cells), bone, and muscle. Multipotent means they can develop into multiple types of cells, but divide a limited number of times (a built in safety mechanism). They are messengers that signal your body to activate self-healing and regeneration. The MSCs themselves do not create new tissue or healing, they signal your body to activate a cascade of cellular functions. As we age, we have fewer mesenchymal stem cells, therefore getting a boost of day 0 Mesenchymal Stem Cell Exosomes may help many conditions.

We selected Stem Cell Exosomes for a number of reasons:

Isolating the beneficial signals secreted by stem cells and using them rather than the stem cells themselves are the next generation of therapy.The combination of components make this a powerful therapy.

Components of Amniotic Fluid:

Benefits of Amniotic Fluid:

It is the safest and most effective regenerative biologic therapy option and it does not require surgery.

There are no negative side effects from stem cell exosomes.

How do they work?

Simply stated, Stem Cell Exosomes have an innate intelligence and activate the bodys own self-healing mechanisms. When we are born, we have a vast supply of mesenchymal stem cells (MSCs), but as we age and degenerate, our MSCs degenerate with us. They are only as fit as we are and we lose a significant amount over time. Thats why at about age 35, we cant recover or heal as quickly as we used to. We just do not have as much regenerative power as we did when we were 15.

Stem Cell Exosomes from MSCs seek out inflammation and go where your body needs them to go and become what your body needs them to become. In other words, when having Stem Cell Exosome Therapy, you are giving your body a boost of fresh, day 0, regenerative signaling power to help with healing and repair.

What Stem Cell Exosomes from mesenchymal stem cells do:

Safety

The stem cell exosomes are procured and processed in the United States according to standards and regulations established by the American Association of Tissue Banks (AATB), the United States Food & Drug Administration (FDA). All local donors. Donor ethics and non-reactive FDA approved serological screening includes:

Regulatory Factors

Amniotic fluid allografts have been FDA registered and processed in accordance with 21 CFR 1271 for Homologous Use to cover and protect tissues by providing cushioning, lubrication, and support.

We aim to provide the most effective regenerative therapies to get our patients back to

doing what they love.

View original post here:
Portsmouth, NH Chronic Pain Stem Cell Therapy | The Center ...

In 2014, during a speech in Manchester, Amanda Grappone Osmer made a startling admission.

I know why you hate me, she began, when it came her time to speak at TEDx Amoskeag Millyard. You all have memories of someone like me that takes you back to a time and place that you wish you didnt have to think about.

Your palms start to sweat. Your stomach is in a knot. Like me, your heart races. You just have an overall feeling of dread.

Mentally, you start to make a tally when you see me coming of all the ways you might get ripped off.

She describes further this experience with her at its center.

When you see me, you load up for bear. Because you know you need to, just to get through our conversation, she says.

You hate me because I am a car salesman. A fourth-generation car salesman.

And with a deep breath, she adds, I understand.

Osmers speech spoke to a stereotypical experience someone might have purchasing a car, an experience that she likened to being under the ether and one that her companys philosophy seeks to counter. Her personal mission and that of Grappone Automotive Group in Bow, for which she is CEO, moves well past the showroom to all aspects of the business, employee relationships and the manner in which she leads an engaged community life.

The business mission: Dedication to building lifelong relationships with our team members, guests and community by serving with integrity, kindness and respect.

And ingrained among her personal objectives is being a little bit better than the day before.

Osmer, the keynote speaker for The Keene Sentinels Extraordinary Women Awards on Aug. 24, graduated from the University of New Hampshire with a degree in humanities. In her teens, she worked at her familys dealership, which was started by her great-grandparents in Concord in 1924 as a Gulf service station. It is now five dealerships. But, despite her early work at the dealership, Osmer didnt envision a future for herself in the cars.

In 2001, after school and marriage, she moved to the West Coast, to the North Bay region of San Francisco. Her marriage ended after a short time, leaving her uncertain what to do next. She applied for all sorts of jobs with no luck, she says. Needing something and knowing something about cars, she found herself selling for Lexus of Marin.

I had never sold anything in my life, she says from her second-floor office at Grappones Toyota franchise, not far from the end of Interstate 89. Her notion of sales, she says, was all wrong, and she learned, You have to be nice to people and honest, and you will earn their business.

Three years later, she was back at her family dealership, in charge of fixed operations service, paint and collision. She described this as the hardest job of my life.

It was difficult to find technicians who met company standards, and there were myriad other workforce challenges, not the least of which is that few women run collision and service centers.

I knew nothing about that world, she recalls. It was constant stress.

But it was in this role that she discovered new ways of doing things that would change her and the company she would come to run. She found a mentor in Jeffrey Liker, the author of The Toyota Way, a best-seller at more than 650,000 copies and translated into 27 languages.

Liker, with whom Osmer corresponds, is professor of industrial and operations engineering at the University of Michigan and has written extensively about how Toyotas manufacturing processes employed principles to reduce waste, boost efficiency and create collaborative workforces to solve problems. He has also profiled other companies using these strategies and measurements, first pioneered by W. Edwards Deming in post-World War II Japan.

I fell in love with lean manufacturing, says Osmer, referring to the umbrella term under which these principles exist.

She opens Likers book frequently; her copy is dog-eared, heavily highlighted and fingerprinted and never far from reach. There are, in the lean world, seven categories of waste transport, inventory, motion, waiting, overproduction, over-processing and defects.

Osmer considers it one of her lifes highlights being invited to speak at the headquarters of Dupont in Delaware at a gathering of collision center specialists a conference at which Liker was speaking, too.

Shes asked if Grappone is an efficient operation.

Its a goal, she says candidly, referring to a never-ending focus on continuous improvement.

From the service operation, Osmer was promoted to COO and director of sales. The sales process was going through a similar evolution, she says.

We had peeled away from the current (traditional) way of doing things, she says, referring to the industry standard of commission-based selling. We had to figure out what is our way I really started to notice that we didnt have anyone recognizing the human experience.

The company hired a director of corporate potential a key decision and embarked on strategic planning that led to an unusual, if not dramatically different approach to business. Its primary commitment, she says, is to Grappones 340 employees. They come first in the mission statement by design. Second, the company seeks lifelong relationships with customers and believes this is best achievable if the sales and service experience is not one of negotiation. This, she says, creates integrity and expectations of consistent treatment. Theres a set price for everything, including financing terms. Everyone pays the same, removing the ether to which she referred in her TEDx speech.

Her sales team does not operate on commissions.

It didnt make sense to race to the bottom on pricing, she says.

Having Toyota as a flagship franchise was helpful; expectations of franchises are reasonable, she says, allowing room for Grappones way.

Always trying to be less wasteful as a company, Osmer said an eighth measure of waste also became a Grappone focus the waste of human creativity. Maybe more than any of the other principles, Osmer emphasizes a workplace that allows innovation to occur. As she describes ways this has been manifested, Ron Malachi, the companys inventory pricing specialist, walks by her office.

He ducks in when asked and rattles off several recent problems a team of folks has solved, including storing extra car inventory at a nearby indoor sports facility.

They get some income, and we get a place (to keep the cars), he says.

Osmer is one of five children born to Robert and Beverly Grappone. Her younger brother, Greg, was her only sibling to be part of the business, eventually becoming the groups chief information officer.

Greg, who had health challenges early in his life, developed cutaneous T-cell lymphoma in his 30s. He found he needed a blood stem cell transplant when the disease turned aggressive.

Osmer was a match for the transplant. Treatment involved eradicating Gregs immune system and injecting new stem cells through a transfusion of Osmers blood. The cancer was killed, but a gruesome side effect graft versus host disease took hold. Osmer described the horrific condition that transpired as one that literally hardened his tissues.

Greg died in 2015, leaving behind a wife and a two-year-old daughter.

In his name, Osmer works on a project that would develop a six-mile abandoned rail line into a new bike and walking path that connects to the Northern Rail trail and would link Concord to Lebanon. It is but one page in her deep portfolio of community work.

She says this involvement in social causes is informed by her familys work.

We were always taught its not about us, she says. Dad just didnt get hung up on material things. I dont get upset when I dont have more things. Its better to express me through how much I help people.

She sees herself as dedicated to serving a lot of people, and it starts with the employees, as the mission suggests.

People need to feel safe; psychological safety, physical safety and having flexibility, she says, describing how the company culture is modeled.

In such an environment, creativity is unleashed, efficiencies are found and people are retained. That environment includes an immaculate, welcoming Toyota dealership building that features a grand piano on its second floor a gift to Osmer from her grandfather.

So, its not a surprise that her team of six directors has more than 140 years of collective service to Grappone.

Away from the dealership, Osmers list of community-service positions is extensive and includes: board member, New Hampshire Public Broadcasting System; corporator, Canterbury Shaker Village; board member, The Endowment for Health; member, Partners for Community Wellness; member, New Hampshire Lemon Law Board; advisory member, Spark New Hampshire; advisory member, Stay Work Play New Hampshire; and advisory member, New Hampshire Charitable Foundations New Hampshire Tomorrow Initiative.

Recently, she became involved in President Donald Birx move to reorganize Plymouth State University into seven educational clusters, beginning this fall. They are: arts and technology; education, democracy and social change; exploration and discovery; health and human enrichment; innovation and entrepreneurship; justice and security; and tourism, environment and sustainable development.

I try to go where I can be most useful, she says, adding she prefers, in many cases, serving one term on a board rather than more to allow broader service.

Osmer lives with her husband, Tom, and three children (two girls and a boy) in a log home in Canterbury. The community, known for its Shaker history, suits her in many ways, from the caring she can expect from the Canterbury Library staff if she drops her son off some afternoon, to the wooded setting that allows her to indulge in trail running, to the neighborly warmth of the Canterbury Fair, recently held.

And, its just the right setting to play her banjo, her instrument of choice.

Osmers is a life being well lived and one seemingly grounded in the words she used to finish her TEDx speech.

So, this is not just about car sales. Its not just about a fourth-generation family business in Bow Junction, New Hampshire, she says. Ask yourselves. Do integrity, kindness and respect form the foundation of all of your relationships, with the people you love the most, with the people you work with, with the people you meet every day? Do they?

If they dont, dont worry about it, she says. Just know that you are under the ether with all of the rest of us. And its time to wake up.

See more here:Amanda Grappone Osmer breaks down car sales stereotypes with focus on kindness, integrity - The Keene Sentinel

Read the original post:
New Hampshire Stem Cells | Stem Cell TV

Shorter Recovery Period

The recovery time after lower back surgery can range from 1 to 4 weeks. People with physically challenging jobs may not be able to return to work after back surgery until 8 to 12 weeks after the surgery.

In contrast, people who have had stem cell treatments report a much faster recovery period. For a few days after the procedure, the patient may feel sore at the injection site. However, the discomfort is minimal.

It is possible to return to normal daily activities within a week. The injected cells begin the process of repairing immediately so it is not surprising to note that significant recovery may come in just a few weeks.

Fewer Medications

After back or disc surgery, a patient may be required to take a course of antibiotics or other medication to support the healing process and prevent infection. The doctor may also prescribe painkillers after surgery.

With stem cell treatments, the patient may feel slightly stiff at the treatment area. However, pain can be managed with over-the-counter medications like acetaminophen or rarely prescription medications. In addition, antibiotics are typically not needed.

Read more:
Stem Cell Injection New Hampshire - Boston Stem Cell Center

Our system helps doctors obtain new patients and effectively communicate the benefits of regenerative therapy.We offer a comprehensive approach to build their practice by educating the public in a transparent manner.Our programs include information and marketing for :

Stem Cell Injections & TreatmentsMesenchymal Stem Cell TherapyUmbilical Cord Blood & Whartons Jelly

Our field representatives are currently serving all US states.

Alabama Birmingham Montgomery MobileAlaska Anchorage Fairbanks JuneauArizona Phoenix Tucson MesaArkansas Little Rock Fort Smith FayettevilleCalifornia Los Angeles San Diego San JoseColorado Denver Colorado Springs AuroraConnecticut Bridgeport New Haven HartfordDelaware Wilmington Dover NewarkFlorida Jacksonville Miami TampaGeorgia Atlanta Augusta ColumbusHawaii Honolulu1 Hilo1 Kailua1Idaho Boise Nampa Idaho FallsIllinois Chicago Aurora RockfordIndiana Indianapolis Fort Wayne EvansvilleIowa Des Moines Cedar Rapids DavenportKansas Wichita Overland Park Kansas CityKentucky Louisville Lexington Bowling GreenLouisiana New Orleans2 Shreveport2 Baton RougeMaine Portland Lewiston BangorMaryland Baltimore Frederick GaithersburgMassachusetts Boston Worcester SpringfieldMichigan Detroit Grand Rapids WarrenMinnesota Minneapolis Saint Paul RochesterMississippi Jackson Gulfport BiloxiMissouri Kansas City Saint Louis SpringfieldMontana Billings Missoula Great FallsNebraska Omaha Lincoln BellevueNevada Las Vegas Reno HendersonNew Hampshire Manchester Nashua ConcordNew Jersey Newark Jersey City PatersonNew Mexico Albuquerque Las Cruces Rio RanchoNew York New York City Buffalo RochesterNorth Carolina Charlotte Raleigh GreensboroNorth Dakota Fargo Bismarck Grand ForksOhio Columbus Cleveland CincinnatiOklahoma Oklahoma City Tulsa NormanOregon Portland Salem EugenePennsylvania Philadelphia Pittsburgh AllentownRhode Island Providence Warwick CranstonSouth Carolina Charleston Columbia North CharlestonSouth Dakota Sioux Falls Rapid City AberdeenTennessee Memphis Nashville KnoxvilleTexas Houston San Antonio DallasUtah Salt Lake City West Valley City ProvoVermont Burlington South Burlington RutlandVirginia Virginia Beach Norfolk ChesapeakeWashington Seattle Spokane TacomaWest Virginia Charleston Huntington ParkersburgWisconsin Milwaukee Madison Green BayWyoming Cheyenne Casper Laramie

Originally posted here:
STEM CELL REPRESENTATIVES LLC. - Stem Cells | Stem Cell ...